Community Healthcare Trust Inc Earnings Per Share Disclosure
Year Ended December 31, | |||||||||||||||||
| (Dollars and shares in thousands, except per share data) | 2025 | 2024 | 2023 | ||||||||||||||
| Net income (loss) | $ | 5,102 | $ | (3,181) | $ | 7,714 | |||||||||||
| Participating securities' share in earnings | (3,022) | (2,795) | (2,619) | ||||||||||||||
| Net income (loss), less participating securities' share in earnings | $ | 2,080 | $ | (5,976) | $ | 5,095 | |||||||||||
| Weighted Average Common Shares Outstanding | |||||||||||||||||
Weighted average common shares outstanding | 28,398 | 27,993 | 26,649 | ||||||||||||||
Unvested restricted shares | (1,541) | (1,463) | (1,447) | ||||||||||||||
Weighted average common shares outstanding–Basic | 26,857 | 26,530 | 25,202 | ||||||||||||||
Weighted average common shares–Basic | 26,857 | 26,530 | 25,202 | ||||||||||||||
Dilutive potential common shares (1) | — | — | — | ||||||||||||||
Weighted average common shares outstanding –Diluted | 26,857 | 26,530 | 25,202 | ||||||||||||||
| Basic Income (Loss) per Common Share | $ | 0.08 | $ | (0.23) | $ | 0.20 | |||||||||||
| Diluted Income (Loss) per Common Share | $ | 0.08 | $ | (0.23) | $ | 0.20 | |||||||||||
| _______________ | |||||||||||||||||
(1) For the year ended December 31, 2025, 48,779 shares issuable upon vesting of the performance-based restricted stock units granted to certain employees during 2025 and 2024 were not included in dilutive securities as the performance thresholds for vesting of these units were not met as measured as of December 31,2025 and/or because the effect would have been anti-dilutive. For the year ended December 31, 2024, 77,136 shares issuable upon vesting of the performance-based restricted stock units granted to certain employees during 2024 were not included in dilutive securities as the performance thresholds for vesting of these units were not met as measured as of December 31,2024 and because the effect would have been anti-dilutive due to the loss from continuing operations for the year ended December 31, 2024. The Company had no other potentially dilutive securities for the years ended December 31, 2025, 2024, or 2023. | |||||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 17, 2026 | Showing above |
| 2024 | Feb 18, 2025 | |
| 2023 | Feb 13, 2024 | |
| 2022 | Feb 14, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.